MyoPax Receives FDA Orphan Drug Designation for its Innovative Regenerative Cell Therapy for Exstrophy-Epispadias Complex

MyoPax has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its regenerative cell therapy in Exstrophy-Epispadias Complex (EEC).